Budesonide/formoterol - Zambon SpA

Drug Profile

Budesonide/formoterol - Zambon SpA

Alternative Names: Formoterol/budesonide - Zambon SpA; Z-7200

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Zambon SpA
  • Developer FLUIDDA; Zambon SpA
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 11 Jul 2016 Zambon SpA completes a phase I trial in Healthy volunteers in United Kingdom (NCT02631941)
  • 15 Mar 2016 Biomarkers information updated
  • 17 Dec 2015 Zambon SpA plans a phase I trial in Healthy volunteers in United Kingdom (NCT02631941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top